Department of Nephrology, Monash Medical Centre, Melbourne, Victoria, Australia.
Monash University, Melbourne, Victoria, Australia.
BMJ Open. 2019 Aug 5;9(8):e029541. doi: 10.1136/bmjopen-2019-029541.
Recent advances in genomic technology have allowed better delineation of renal conditions, the identification of new kidney disease genes and subsequent targets for therapy. To date, however, the utility of genomic testing in a clinically ascertained, prospectively recruited kidney disease cohort remains unknown. The aim of this study is to explore the clinical utility and cost-effectiveness of genomic testing within a national cohort of patients with suspected genetic kidney disease who attend multidisciplinary renal genetics clinics.
This is a prospective observational cohort study performed at 16 centres throughout Australia. Patients will be included if they are referred to one of the multidisciplinary renal genetics clinics and are deemed likely to have a genetic basis to their kidney disease by the multidisciplinary renal genetics team. The expected cohort consists of 360 adult and paediatric patients recruited by December 2018 with ongoing validation cohort of 140 patients who will be recruited until June 2020. The primary outcome will be the proportion of patients who receive a molecular diagnosis via genomic testing (diagnostic rate) compared with usual care. Secondary outcomes will include change in clinical diagnosis following genomic testing, change in clinical management following genomic testing and the cost-effectiveness of genomic testing compared with usual care.
The project has received ethics approval from the Melbourne Health Human Research Ethics Committee as part of the Australian Genomics Health Alliance protocol: HREC/16/MH/251. All participants will provide written informed consent for data collection and to undergo clinically relevant genetic/genomic testing. The results of this study will be published in peer-reviewed journals and will also be presented at national and international conferences.
基因组技术的最新进展使得更好地区分肾脏疾病、识别新的肾脏疾病基因以及为治疗提供后续靶点成为可能。然而,到目前为止,基因组检测在临床确定的、前瞻性招募的肾脏疾病队列中的效用仍然未知。本研究旨在探索基因组检测在澳大利亚 16 个中心的多学科肾脏遗传学诊所中疑似遗传性肾脏疾病患者的临床应用价值和成本效益。
这是一项在澳大利亚的 16 个中心进行的前瞻性观察性队列研究。如果患者被转介到多学科肾脏遗传学诊所之一,并且多学科肾脏遗传学团队认为他们的肾脏疾病可能具有遗传基础,则将其纳入研究。预计队列将包括 2018 年 12 月前招募的 360 名成年和儿科患者,以及 2020 年 6 月前招募的 140 名持续验证队列患者。主要结局将是通过基因组检测获得分子诊断的患者比例(诊断率)与常规护理相比。次要结局将包括基因组检测后临床诊断的变化、基因组检测后临床管理的变化以及与常规护理相比基因组检测的成本效益。
该项目已获得墨尔本健康人类研究伦理委员会的伦理批准,作为澳大利亚基因组健康联盟协议的一部分:HREC/16/MH/251。所有参与者都将提供书面知情同意书,同意进行数据收集和进行临床相关的遗传/基因组检测。本研究的结果将发表在同行评议的期刊上,并将在国内外会议上进行展示。